SOX2 promotes tumor growth of esophageal squamous cell carcinoma through the AKT/mammalian target of rapamycin complex 1 signaling pathway

Cancer Science

Volumn 104, Issue 7, 2013, Pages 810-816

  Gen, Yasuyuki ^a   Yasui, Kohichiroh ^a   Nishikawa, Taichiro ^a   Yoshikawa, Toshikazu ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 MORPHOLINO 8 PHENYLCHROMONE; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PHOSPHOPROTEIN; PROTEIN KINASE B; RAPAMYCIN; TRANSCRIPTION FACTOR SOX2;

ANIMAL CELL; APOPTOSIS; ARTICLE; CANCER GROWTH; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TISSUE MICROARRAY;

ANIMALS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CHROMONES; ESOPHAGEAL NEOPLASMS; HETEROGRAFTS; HUMANS; MALE; MAP KINASE SIGNALING SYSTEM; MICE; MICE, INBRED BALB C; MICE, NUDE; MORPHOLINES; MULTIPROTEIN COMPLEXES; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; SIROLIMUS; SOXB1 TRANSCRIPTION FACTORS; TOR SERINE-THREONINE KINASES;

EID: 84880715864     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12155     Document Type: Article

References (32)

1. Pevny LH, Lovell-Badge R. Sox genes find their feet. Curr Opin Genet Dev 1997; 7: 338-44.
2. Wegner M. From head to toes: the multiple facets of Sox proteins. Nucleic Acids Res 1999; 27: 1409-20.
3. Kamachi Y, Uchikawa M, Kondoh H. Pairing SOX off: with partners in the regulation of embryonic development. Trends Genet 2000; 16: 182-7.
4. Masui S, Nakatake Y, Toyooka Y et al. Pluripotency governed by Sox2 via regulation of Oct3/4 expression in mouse embryonic stem cells. Nat Cell Biol 2007; 9: 625-35.
5. Fong H, Hohenstein KA, Donovan PJ. Regulation of self-renewal and pluripotency by Sox2 in human embryonic stem cells. Stem Cells 2008; 26: 1931-8.
6. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006; 126: 663-76.
7. Takahashi K, Tanabe K, Ohnuki M et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007; 131: 861-72.
8. Yamanaka S. Strategies and new developments in the generation of patient-specific pluripotent stem cells. Cell Stem Cell 2007; 1: 39-49.
9. Que J, Okubo T, Goldenring JR et al. Multiple dose-dependent roles for Sox2 in the patterning and differentiation of anterior foregut endoderm. Development 2007; 134: 2521-31.
10. Ishii Y, Rex M, Scotting PJ, Yasugi S. Region-specific expression of chicken Sox2 in the developing gut and lung epithelium: regulation by epithelial-mesenchymal interactions. Dev Dyn 1998; 213: 464-75.
11. Tsukamoto T, Inada K, Tanaka H et al. Down-regulation of a gastric transcription factor, Sox2, and ectopic expression of intestinal homeobox genes, Cdx1 and Cdx2: inverse correlation during progression from gastric/intestinal-mixed to complete intestinal metaplasia. J Cancer Res Clin Oncol 2004; 130: 135-45.
12. Williamson KA, Hever AM, Rainger J et al. Mutations in SOX2 cause anophthalmia-esophageal-genital (AEG) syndrome. Hum Mol Genet 2006; 15: 1413-22.
13. Gen Y, Yasui K, Zen Y et al. SOX2 identified as a target gene for the amplification at 3q26 that is frequently detected in esophageal squamous cell carcinoma. Cancer Genet Cytogenet 2010; 202: 82-93.
14. Bass AJ, Watanabe H, Mermel CH et al. SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet 2009; 41: 1238-42.
15. Long KB, Hornick JL. SOX2 is highly expressed in squamous cell carcinomas of the gastrointestinal tract. Hum Pathol 2009; 40: 1768-73.
16. Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2002; 2: 489-501.
17. Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 2006; 7: 606-19.
18. Wei L, Xu Z. Cross-signaling among phosphinositide-3 kinase, mitogen-activated protein kinase and sonic hedgehog pathways exists in esophageal cancer. Int J Cancer 2011; 129: 275-84.
19. Li B, Tsao SW, Li YY et al. Id-1 promotes tumorigenicity and metastasis of human esophageal cancer cells through activation of PI3K/AKT signaling pathway. Int J Cancer 2009; 125: 2576-85.
20. Sansal I, Sellers WR. The biology and clinical relevance of the PTEN tumor suppressor pathway. J Clin Oncol 2004; 22: 2954-63.
21. Hu YC, Lam KY, Tang JC, Srivastava G. Mutational analysis of the PTEN/MMAC1 gene in primary oesophageal squamous cell carcinomas. Mol Pathol 1999; 52: 353-6.
22. Ding Y, Shimada Y, Kano M et al. PTEN/MMAC1 expression in esophageal squamous cell carcinomas. Int J Oncol 2000; 17: 695-9.
23. Skeen JE, Bhaskar PT, Chen CC et al. Akt deficiency impairs normal cell proliferation and suppresses oncogenesis in a p53-independent and mTORC1-dependent manner. Cancer Cell 2006; 10: 269-80.
24. Bhaskar PT, Hay N. The two TORCs and Akt. Dev Cell 2007; 12: 487-502.
25. Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell 2007; 12: 9-22.
26. Shimada Y, Imamura M, Wagata T, Yamaguchi N, Tobe T. Characterization of 21 newly established esophageal cancer cell lines. Cancer 1992; 69: 277-84.
27. Gen Y, Yasui K, Zen K et al. A novel amplification target, ARHGAP5, promotes cell spreading and migration by negatively regulating RhoA in Huh-7 hepatocellular carcinoma cells. Cancer Lett 2009; 275: 27-34.
28. Hu L, Hofmann J, Lu Y, Mills GB, Jaffe RB. Inhibition of phosphatidylinositol 3′-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models. Cancer Res 2002; 62: 1087-92.
29. Couderc C, Poncet G, Villaume K et al. Targeting the PI3K/mTOR pathway in murine endocrine cell lines: in vitro and in vivo effects on tumor cell growth. Am J Pathol 2011; 178: 336-44.
30. Chen Y, Shi L, Zhang L et al. The molecular mechanism governing the oncogenic potential of SOX2 in breast cancer. J Biol Chem 2008; 283: 17969-78.
31. Kondoh H, Kamachi Y. SOX-partner code for cell specification: regulatory target selection and underlying molecular mechanisms. Int J Biochem Cell Biol 2010; 42: 391-9.
32. Pal SK, Reckamp K, Yu H, Figlin RA. Akt inhibitors in clinical development for the treatment of cancer. Expert Opin Investig Drugs 2010; 19: 1355-66.